10 papers analyzed
These studies suggest that resistance to targeted cancer therapies involves genetic and nongenetic mechanisms, including mutations, epigenetic changes, signaling pathways, and tumor microenvironment interactions.
The development of resistance to targeted cancer therapies is a significant challenge in the treatment of various cancers. Despite initial effectiveness, many patients eventually experience disease progression due to the emergence of resistance mechanisms. Understanding these mechanisms is crucial for improving therapeutic strategies and patient outcomes.
Secondary Mutations and Target Modifications:
Activation of Bypass Pathways:
Intratumoral Heterogeneity and Minimal Residual Disease:
Epigenetic Changes and Chromatin Remodeling:
Immune-Based Resistance Mechanisms:
Role of MicroRNAs (miRNAs):
Non-Genetic Mechanisms:
Resistance to targeted cancer therapies is multifaceted, involving genetic mutations, activation of bypass pathways, intratumoral heterogeneity, epigenetic changes, immune-based mechanisms, and the role of miRNAs. Addressing these diverse mechanisms requires a comprehensive approach, including combination therapies and novel strategies to preemptively target potential resistance pathways. Understanding and targeting these mechanisms can improve the efficacy and durability of cancer treatments.
Deep-Learning Based Linear Precoding for MIMO Channels with Finite-Alphabet Signaling.
Minecraft
How does theatre impact children?
What are the symptoms of neurological disorders?
pneumonia
How much Copper should I take daily?